This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

ASCO-GU 2023: The DEAR study

Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

NUBEQA® (darolutamide)

Description

In this on-demand video, Professor Robert Jones gives an update on a congress highlight presented at the 2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Symposium. Professor Jones discusses the results of the DEAR study on the real-world utilisation and outcomes of darolutamide, enzalutamide, and apalutamide in patients with nmCRPC, including discontinuation data and data on progression to metastatic castration-resistant prostate cancer (mCRPC).

NUBEQA Prescribing Information

Speakers
    • Professor Robert Jones
      Professor Robert Jones

    Professor Jones is Director, Cancer Clinical Trials Unit for Scotland, professor of clinical cancer research at the University of Glasgow and a consultant medical oncologist at the Beatson West of Scotland Cancer Centre.

    After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research. He currently chairs the UK National Clinical Research Institute’s Bladder and Renal research group.

BAUS 2024: Imaging and nmCRPC
NUBEQA® (darolutamide)
PP-NUB-GB-2081, January 2025
BAUS 2024: Urology and Oncology in Partnership
NUBEQA® (darolutamide)
PP-NUB-GB-2080, January 2025
BAUS 2024: Management of CV toxicity and bone health
NUBEQA® (darolutamide)
PP-NUB-GB-2079, January 2025

PP-NUB-GB-2022 | January 2025